Reviews/Giant Cell Arteritis/Glucocorticoid monotherapy relapses on taper
Glucocorticoid · GCA-GC-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This claim asks whether people with giant cell arteritis treated with steroids alone tend to flare again while the steroid dose is being reduced. Across the studies here, the answer is consistently yes: in two trials where the comparison group received steroids only, relapse or flare came early and often [1][8], and several real-world groups of steroid-treated patients found that roughly half or more relapsed during tapering [2][3][5]. These results come from different countries and different study types, which is why the panel treated the direction as settled. The main caveats are that 'frequently' is not pinned to a single number and that studies counted relapse differently, with some counting mild blood-marker rises [2][3][4]. One rapid-taper group showed a third of patients stayed relapse-free, so frequent is not the same as inevitable [3]. None of the studies showed steroid monotherapy rarely relapsing.
Two randomised trials whose comparison arms received glucocorticoids only during taper show early, frequent relapse: in [1] only 20% of the placebo arm were relapse-free at 52 weeks, and in [8] median time to first flare on placebo was 179-224 days versus 575-577 days on weekly tocilizumab. Independent glucocorticoid-only or glucocorticoid-based cohorts converge: [2] reports relapse in 43.6% and 48.3% of early and late GCA during tapering at a methyl-prednisolone dose of 6 mg, [3] reports 68% relapsed on glucocorticoids only, and [5] reports relapse in 47.9% overall. [6] states glucocorticoids fail to induce sustained remission in approximately half of patients, and [4] describes relapse after remission in a registry of glucocorticoid-treated patients. The signal is directionally uniform across Switzerland, Slovenia, Basel, Japan, Canada and the multicentre GiACTA trial. The contested point: The division is over what 'frequently' means, not over direction: reported rates span 34.5% [4] to 80% not relapse-free [1] under heterogeneous definitions, with [2] and [4] counting isolated CRP re-elevation and [3] noting most relapses were minor and two-thirds were isolated raised inflammatory markers. [3] also shows a third of patients remained relapse-free on a rapid taper, so the frequency is high but not invariant.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Giant Cell Arteritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
'Frequently' is unquantified and reported relapse rates span 34.5%-80%; several cohorts ([2],[4]) count isolated CRP re-elevation and [3] notes most relapses were minor with 2/3 isolated raised inflammatory markers, so the headline frequency partly reflects liberal relapse definitions rather than clinically major relapse.
Not all cited cohorts are pure GC monotherapy: [4] had 29.4% on concomitant immunosuppressants at baseline and [5] pools GC+OIS groups, while [7]'s relapse data are for TCZ/MTX, so the monotherapy-specific frequency is partly inferred.
Where it remains uncertain. Relapse definitions vary and some rely on isolated inflammatory-marker rises ([2][3][4]), and one rapid-taper cohort left 32% relapse-free [3], so 'frequently' is directional rather than a fixed rate.
Aleatory
Even on identical tapering some patients relapse early and others stay relapse-free ([3] 32% relapse-free; [1] 20% relapse-free), so individual outcomes are inherently variable.
Epistemic
Reported rates range from 34.5% [4] to 80% not relapse-free [1] with no agreed threshold for what 'frequently' denotes.
Inferential
[4] had 29.4% on concomitant immunosuppressants, [5] pools GC+OIS and [7]'s relapse data are for TCZ/MTX, so pure-monotherapy frequency is partly extrapolated.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT placebo arm is GC monotherapy; 20% relapse-free means 80% relapsed during taper.
“Relapse-free survival was achieved in 17 (85%) patients in the tocilizumab group and two (20%) in the placebo group by week 52 (risk difference 65%, 95% CI 36-94; p=0·0010).”
Panel auditInternal validity: medium · scope of inference: New-onset or relapsing GCA patients aged ≥50 on a standardised prednisolone taper at one Swiss centre.Key limitations: small single-centre trial · monotherapy inferred from placebo arm · wide confidence interval
Prospective cohort on GC: ~44-48% relapse during taper at low steroid dose.
“GCA relapsed in 17/39 (43.6%) and 14/29 (48.3%) in early and late GCA, respectively. The median (IQR) time to the first relapse was 24.8 (13.6-46.5) weeks (early GCA 14 (13-34) weeks; late GCA 25 (22-48) weeks, P = 0.117), at the methyl-prednisolone dose of 6.0 (4.0-12.0) mg.”
Panel auditInternal validity: medium · scope of inference: 68 newly diagnosed GCA patients on glucocorticoid tapering at one Slovenian rheumatology centre.Key limitations: single centre · no control arm · relapse rate descriptive
GC-only cohort: 68% relapsed during taper at median 8 mg; direct.
Panel auditInternal validity: medium · scope of inference: 47 newly diagnosed GCA patients on a planned 26-week rapid glucocorticoid taper at one Swiss centre.Key limitations: single centre · retrospective records · most relapses minor
Registry evidence that relapse after remission is common under GC-based therapy.
“Overall, 41 (34.5%) of the 119 patients had poor treatment outcomes; 13 did not achieve clinical remission by week 24, and 28 had a relapse after achieving clinical remission.”
Panel auditInternal validity: medium · scope of inference: 119 newly diagnosed GCA patients on glucocorticoids (some with concomitant immunosuppressants) across a Japanese registry.Key limitations: retrospective registry · not pure monotherapy · relapse rate descriptive
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent RCT placebo arms and cohorts directly and consistently show frequent relapse of GCA on glucocorticoid monotherapy during taper, with only definitional and mixed-therapy caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Harmonised major-relapse definition. Reported frequencies span 34.5%-80% partly because studies count relapse differently, including isolated CRP re-elevation ([2][4]) and mostly minor events [3]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective glucocorticoid-monotherapy cohort applying a single pre-specified definition that separates clinically major relapse from isolated inflammatory-marker rise, reported during taper.
Open question: What share of relapses during glucocorticoid monotherapy taper are clinically major rather than isolated inflammatory-marker rises? Why it is still open: [3] reports most relapses were minor with two-thirds isolated raised inflammatory markers, while [2] and [4] count CRP re-elevation as relapse, so the major-relapse fraction is unresolved.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19